Acyclovir-Loaded Solid Lipid Nanoparticles: Optimization, Characterization and Evaluation of Its Pharmacokinetic...

Area of Science:

• Nanotechnology
• Pharmacology
• Drug Delivery Systems

Background:

• Acyclovir, an antiviral for herpes simplex virus, has low oral bioavailability requiring frequent high doses.
• Current acyclovir regimens can cause adverse effects, necessitating improved drug delivery methods.
• Solid lipid nanoparticles (SLNs) offer a potential solution for enhanced drug delivery.

Purpose of the Study:

• To develop and characterize acyclovir-loaded solid lipid nanoparticles (SLNs).
• To evaluate the in vivo pharmacokinetic parameters of acyclovir-loaded SLNs.
• To assess the potential of SLNs as an oral delivery vehicle for acyclovir.

Main Methods:

• Solid lipid nanoparticles (SLNs) were formulated using Biogapress Vegetal 297 ATO and Tween 80.
• Response surface methodology was employed to optimize SLN composition.
• Particle size analysis determined optimal SLN characteristics (134 nm).
• In vivo pharmacokinetic studies compared acyclovir-loaded SLNs with commercial acyclovir suspension.

Main Results:

• Optimized SLNs were successfully developed with a particle size of 134 nm.
• Acyclovir-loaded SLNs demonstrated significantly enhanced oral bioavailability compared to the commercial suspension.
• The plasma concentration of acyclovir from SLNs was four times higher than the suspension.

Conclusions:

• Solid lipid nanoparticles (SLNs) are a feasible and effective oral delivery system for acyclovir.
• This nanoparticulate drug delivery system offers a promising new therapeutic approach for acyclovir treatment.
• The developed SLN formulation enhances acyclovir bioavailability, potentially reducing dosing frequency and side effects.